Large NIH Clinical Trial Illuminates Long-Term Health Effects of HIV

Cross-posted from NIAID Now BlogInitial data from a large NIH-supported clinical trial offer a detailed look at the health status of people aging with HIV around the world. With 7,770 participants enrolled in 12 countries across five continents, the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) is evaluating the ability of a statin medication, pitavastatin, to

Law Everywhere: A Causal Framework for Law and Infectious Disease – Aaron J. Siegler, Kelli A. Komro, Alexander C. Wagenaar, 2020

This supplement on HIV, hepatitis, sexually transmitted disease, and tuberculosis is timely and important because it highlights the many ways that law, regulation, and institutional policy affect the incidence and prevalence of infectious disease. Law is a causal factor that deserves careful scientific research attention, not only because it is central to understanding disease variation across…

Ready, Set, PrEP

Ready, Set, PrEP Program Removes Cost Barrier to Increase Access to PrEP Medications NationwideReady, Set, PrEP is a new nationwide program led by HHS that provides PrEP medications at no cost to thousands of individuals who qualify. The program will expand access to PrEP medications, reduce new HIV infections, and bring us one step closer to ending the HIV epidemic in the United States.

Partners | HIV | CDC

CDC provides leadership for HIV prevention research and surveillance and the development and testing of effective biomedical interventions to reduce transmission and HIV disease progression in the United States and internationally. It also provides national leadership in the development, implementation, and evaluation of evidence-based HIV prevention programs serving persons affected by, or at…

Ready, Set, PrEP

Ready, Set, PrEP Program Removes Cost Barrier to Increase Access to PrEP Medications NationwideReady, Set, PrEP is a new nationwide program led by HHS that provides PrEP medications at no cost to thousands of individuals who qualify. The program will expand access to PrEP medications, reduce new HIV infections, and bring us one step closer to ending the HIV epidemic in the United States.

Screening for HIV | Clinicians | HIV | CDC

Clinical practice materials and tools, provider training and continuing education, and guidelines and scientific evidence to make screening a part of daily routine care. There are also links to topics and resources on partner services, prevention of co-morbidities, and advantages of new HIV tests. Other topics include following up with patients, delivering HIV test results, and discussing sexual…